NASDAQ:GPCR - Get Free Report )'s stock price rose 8% during trading on Thursday . The stock traded as high as $39.33 and last traded at $39.33. Approximately 179,570 shares changed hands during trading, a decline of 68% from the average daily volume of 564,966 shares. The stock had previously closed at $36.43.
Get Structure Therapeutics alerts:
Sign Up
Analyst Ratings Changes GPCR has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Thursday, April 18th. Lifesci Capital restated an "outperform" rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $85.71.
View Our Latest Analysis on GPCR
Structure Therapeutics Stock Up 7.0 % The firm has a market cap of $1.82 billion and a price-to-earnings ratio of -47.39. The business has a 50 day moving average price of $39.91 and a 200-day moving average price of $48.01.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report ) last posted its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. Research analysts anticipate that Structure Therapeutics Inc. will post -0.98 earnings per share for the current fiscal year.
Institutional Inflows and Outflows Large investors have recently bought and sold shares of the company. Barclays PLC bought a new position in Structure Therapeutics during the 2nd quarter worth approximately $47,000. Picton Mahoney Asset Management bought a new position in Structure Therapeutics during the 3rd quarter worth approximately $116,000. Sectoral Asset Management Inc. acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $139,000. ADAR1 Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $163,000. Finally, Washington University acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $215,000. Institutional investors own 91.78% of the company's stock.
About Structure Therapeutics (
Get Free Report )
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
